Farncombe Family Digestive Health Research Institute, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
Gastroenterol Clin North Am. 2010 Sep;39(3):709-20. doi: 10.1016/j.gtc.2010.08.020.
Many gastrointestinal diseases remain poorly responsive to therapies, and even in the cases of conditions for which there are many effective drugs, there is still considerable room for improvement. This article is focused on drugs for digestive disorders that have entered the marketplace recently, or are expected to reach the marketplace within the next 1 to 2 years. Although advances have been made in understanding gastrointestinal motility, visceral pain, mucosal inflammation, and tissue repair, the major gastrointestinal diseases remain as significant therapeutic challenges.
许多胃肠道疾病对治疗的反应仍然不佳,即使对于有许多有效药物的疾病,仍有很大的改进空间。本文主要关注最近进入市场或预计在未来 1 至 2 年内进入市场的消化疾病药物。尽管在胃肠道动力、内脏疼痛、粘膜炎症和组织修复方面已经取得了进展,但主要的胃肠道疾病仍然是重大的治疗挑战。